Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Autolus Therapeutics Plc ADR (AUTL)

Autolus Therapeutics Plc ADR (AUTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 380,585
  • Shares Outstanding, K 266,143
  • Annual Sales, $ 10,120 K
  • Annual Income, $ -220,660 K
  • EBIT $ -263 M
  • EBITDA $ -255 M
  • 60-Month Beta 1.98
  • Price/Sales 7.44
  • Price/Cash Flow N/A
  • Price/Book 1.46

Options Overview Details

View History
  • Implied Volatility 383.11% (-36.82%)
  • Historical Volatility 81.38%
  • IV Percentile 80%
  • IV Rank 49.73%
  • IV High 697.19% on 11/10/25
  • IV Low 72.43% on 05/20/25
  • Expected Move (DTE 9) 0.0425 (2.97%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 386
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 20,181
  • Open Int (30-Day) 18,655
  • Expected Range 1.3875 to 1.4725

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.27
  • Number of Estimates 3
  • High Estimate -0.22
  • Low Estimate -0.32
  • Prior Year -0.09
  • Growth Rate Est. (year over year) -200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3100 +9.16%
on 02/05/26
1.7900 -20.11%
on 01/12/26
-0.3800 (-20.99%)
since 01/09/26
3-Month
1.2000 +19.17%
on 11/21/25
2.0700 -30.92%
on 01/07/26
-0.0700 (-4.67%)
since 11/11/25
52-Week
1.1050 +29.41%
on 04/11/25
2.7000 -47.04%
on 07/24/25
-0.4800 (-25.13%)
since 02/11/25

Most Recent Stories

More News
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.4300 (unch)
Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026

Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025 Autolus anticipates...

AUTL : 1.4300 (unch)
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform

SOUTH SAN FRANCISCO, Calif. and LONDON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering...

AUTL : 1.4300 (unch)
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform

Autolus will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indications

AUTL : 1.4300 (unch)
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025

Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cells All patients show deep B-cell...

AUTL : 1.4300 (unch)
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune effector...

AUTL : 1.4300 (unch)
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.4300 (unch)
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed...

AUTL : 1.4300 (unch)
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

LONDON and GAITHERSBURG, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.4300 (unch)
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Company reports Q3 2025 AUCATZYL ® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of target Clinical execution and data generation...

AUTL : 1.4300 (unch)

Business Summary

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London,...

See More

Key Turning Points

3rd Resistance Point 1.5383
2nd Resistance Point 1.4967
1st Resistance Point 1.4633
Last Price 1.4300
1st Support Level 1.3883
2nd Support Level 1.3467
3rd Support Level 1.3133

See More

52-Week High 2.7000
Fibonacci 61.8% 2.0907
Fibonacci 50% 1.9025
Fibonacci 38.2% 1.7143
Last Price 1.4300
52-Week Low 1.1050

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar